Pfizer Inc. (PFE): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts

Pfizer Inc. (PFE) has been a subject of interest among analysts and investors alike, with many seeing the pharmaceutical giant as an attractive investment opportunity. The company's recent financial performance and growth prospects have analysts bullish on the stock, despite some headwinds and patent expirations on the horizon. This article will delve into the reasons why Pfizer is considered a cheap pharmaceutical stock to buy, according to analysts, and explore the company's long-term growth potential.

Pfizer's recent financial performance has been mixed, with revenue growth lagging behind some of its peers in the pharmaceutical industry. However, the company's earnings growth has been impressive, with a 111.35% increase from the previous year. This strong earnings growth, coupled with a relatively low forward P/E ratio of 8.81, suggests that Pfizer's stock may be undervalued compared to its historical averages and industry peers.